Ubs Asset Management Americas Inc Alx Oncology Holdings Inc Transaction History

Ubs Asset Management Americas Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$5.84 - $17.56 $127,446 - $383,211	21,823 New	21,823 $131,000
Q1 2023 May 15, 2023	BUY	$4.52 - $11.71 $52,346 - $135,613	11,581 New	11,581 $52,000
Q2 2022 Aug 12, 2022	SELL	$5.89 - $19.46 $2.08 Million - $6.86 Million	-352,402 Reduced 96.38%	13,251 $107,000
Q1 2022 May 16, 2022	BUY	$13.65 - $22.06 $182,923 - $295,626	13,401 Added 3.8%	365,653 $6.18 Million
Q4 2021 Feb 14, 2022	BUY	$21.49 - $74.4 $1.72 Million - $5.95 Million	79,915 Added 29.34%	352,252 $7.57 Million
Q3 2021 Nov 15, 2021	SELL	$52.51 - $80.91 $199,327 - $307,134	-3,796 Reduced 1.37%	272,337 $20.1 Million
Q2 2021 Aug 16, 2021	BUY	$52.2 - $75.23 $4.87 Million - $7.02 Million	93,273 Added 51.01%	276,133 $15.1 Million
Q1 2021 May 14, 2021	BUY	$62.84 - $87.68 $9.4 Million - $13.1 Million	149,651 Added 450.63%	182,860 $13.5 Million
Q4 2020 Mar 01, 2021	BUY	$34.11 - $112.26 $1.13 Million - $3.73 Million	33,209 New	33,209 $2.86 Million

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $68.9M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.